Elaine D. Sun
2021
In 2021, Elaine D. Sun earned a total compensation of $2.2M as Senior Vice President Chief Financial Officer at Halozyme Therapeutics, a 36% decrease compared to previous year.
Compensation breakdown
| Option Awards | $495,009 |
|---|---|
| Salary | $494,000 |
| Stock Awards | $1,155,062 |
| Other | $14,271 |
| Total | $2,158,342 |
Sun received $1.2M in stock awards, accounting for 54% of the total pay in 2021.
Sun also received $495K in option awards, $494K in salary and $14.3K in other compensation.
Rankings
In 2021, Elaine D. Sun's compensation ranked 5,759th out of 12,405 executives tracked by ExecPay. In other words, Sun earned more than 53.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,759 out of 12,405 | 54th |
Division Manufacturing | 2,441 out of 5,494 | 56th |
Major group Chemicals And Allied Products | 1,056 out of 2,369 | 55th |
Industry group Drugs | 943 out of 2,090 | 55th |
Industry Biological Products, Except Diagnostic Substances | 231 out of 452 | 49th |
Pay ratio
| Elaine D. Sun's Pay | $2,158,342 |
|---|---|
| Median Employee's Pay | $291,734 |
| Pay Ratio | 7to 1 |
In 2021, the annual total compensation of Elaine D. Sun was $2,158,342.
The annual total compensation of the median employee at Halozyme Therapeutics was $291,734.
The ratio of Elaine D. Sun's pay to the pay of median employee was therefore 7 to one.
Source: SEC filing on March 25, 2022.
Sun's colleagues
We found three more compensation records of executives who worked with Elaine D. Sun at Halozyme Therapeutics in 2021.